Literature DB >> 26648971

DWI Lesion Patterns in Cancer-Related Stroke--Specifying the Phenotype.

Christopher Jan Schwarzbach1, Marc Fatar1, Philipp Eisele1, Anne D Ebert1, Michael G Hennerici1, Kristina Szabo1.   

Abstract

BACKGROUND: Due to the lack of specific diagnostic markers, the diagnosis of cancer-related stroke strongly depends on its phenotype. Distinct DWI lesion patterns with involvement of multiple vascular territories have been reported repeatedly in cancer-related stroke but have not been addressed in detail in a selected cohort of prospectively recruited cancer patients with emphasis on hypercoagulable conditions. PATIENTS AND METHODS: Ischemic stroke patients with known malignant cancer activity, laboratory evidence of strong plasmatic hypercoagulation (D-dimer levels > 3 µg/ml) and without competing stroke etiologies according to the recently introduced ASCOD (A - atherosclerosis, S - small vessel disease, C - cardiac pathology, O - other cause, and D - dissection) classification of evidence-rated etiology of stroke subtypes were included in the analysis. Cerebral MRI on admission was reviewed with respect to ischemic lesion patterns.
RESULTS: Thirty-two patients met the inclusion criteria. The mean D-dimer levels were 15.39 µg/ml (± 10.84). Acute infarction in ≥ 2 vascular territories was present in 27/32 (84%) patients. (Micro-) embolic scattering of infarction was present in 25/32 (78%) patients. Evidence for previous, potentially oligosymptomatic infarction was found in 16 (50%) patients, demonstrated by the additional presence of subacute or chronic ischemic lesions.
CONCLUSION: When excluding competing embolic and nonembolic stroke etiologies, the pattern of scattered DWI lesions in multiple vascular supply territories strongly dominates the phenotype of cancer-related stroke. Additionally, evidence of recurrent infarction is frequent in this cohort of patients. This is not only important for the diagnosis of cancer-related stroke itself but may prove helpful for the identification of cancer-related stroke patients with unknown malignancy at the time of stroke manifestation and evaluation of strategies for secondary prevention.

Entities:  

Keywords:  Acute stroke; Cerebral embolism; Diagnostic criteria; Embolic stroke; MRI-DWI; Recurrent stroke; Risk factors for stroke; Stroke and cancer

Mesh:

Substances:

Year:  2015        PMID: 26648971      PMCID: PMC4662270          DOI: 10.1159/000439549

Source DB:  PubMed          Journal:  Cerebrovasc Dis Extra        ISSN: 1664-5456


Background

Ischemic stroke and cancer represent a frequent coincidence with large-scale significance on stroke etiology, diagnostics and treatment options. Evidence from early autopsy and recent clinical studies suggest a prevalence of ischemic stroke in cancer patients of approximately 3% [1,2]. Considering the annual incidence of cancer in Germany published by the Robert Koch Institute in 2012, this number would imply 15,000 affected stroke patients in Germany each year [3]. In practice, however, these numbers are much smaller as the association of stroke and cancer often remains unappreciated. This is due to the fact that cancer-related stroke is underestimated and difficult to diagnose, in particular in patients without a known cancer history or unrecognized stroke subtype patterns. Owing to the lack of specific diagnostic markers, the diagnosis of cancer-related stroke strongly depends on its phenotype, which is determined by the interrelation of cancer-related hypercoagulation and concomitant arterial embolism [4,5]. DWI-MRI is exquisitely sensitive to detect areas of acute ischemic tissue change [6] and has improved the understanding of distinct pathophysiological mechanisms leading to ischemia in several subgroups of stroke with differences in patterns considering lesion size, localization and distribution [7,8,9]. Specifying DWI lesions in cancer-related stroke may therefore amplify our understanding of the pathophysiological mechanisms, which take effect in patients with cancer-related stroke and, moreover, may be easily applied to help identifying patients affected by cancer-related stroke mechanisms. On the basis of the contemporary pathophysiological perception of cancer-related stroke, we hypothesized that embolic stroke patterns would be dominant in this selected cohort of stroke patients.

Patients and Methods

Patient Selection

Patients with acute ischemic stroke, the additional diagnosis of solid and active malignancy, laboratory evidence of strong plasmatic hypercoagulation (D-dimer levels >3 µg/ml) and without competing stroke etiologies according to the ASCOD (A – atherosclerosis, S – small vessel disease, C – cardiac pathology, O – other cause, and D – dissection) classification of evidence-rated etiology of stroke subtypes [10] were included in the analysis. Participants were recruited from our comprehensive stroke center (Department of Neurology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany) and identified by our prospectively collected stroke data bank for the years 2004-2014. Active cancer was defined as confirmed malignancy treated or untreated in the last 6 months before stroke. Diagnosis of cancer was confirmed by given medical records or, in case of newly diagnosed or recurrent cancer, by histological evidence and oncologist expertise. Patients with hematologic malignancies or primary brain tumor were not included in the study because these patients were considered to represent a subgroup with different underlying stroke mechanisms.

Clinical Management and Data Acquisition

Type of cancer, stroke etiology and D-dimer levels were identified consistently by reviewing each patient. D-dimer levels were assessed at the time of hospitalization. Full stroke workup included extra- and intracranial Doppler and duplex sonography of brain-supplying arteries, electrocardiography on admission, 72 h of electrocardiographic and vital sign monitoring, transthoracic or transesophageal echocardiography and laboratory tests (routine hematology and biochemistry, including coagulation test) as standard procedures according to stroke unit management recommendations (European Stroke Organization Guidelines, 2008). Patients without sufficient MRI at the time of hospitalization were excluded from the analysis.

MRI Assessment and Analysis

The MRI investigations were performed on 1.5-tesla and 3.0-tesla MRI scanners (MAGNETOM Sonata, Trio or Skyra; Siemens, Erlangen, Germany). The scanning protocol included transversal DWI, T2-weighted fluid-attenuated inversion recovery, T1- and T2-weighted images, obtained with a 5-mm slice thickness, and an MR angiography. The acute lesion pattern on DWI was characterized according to number and localization with regard to the affected vascular territory (fig. 1). The presence of (micro-) embolic lesions was documented, defined as >5 scattered small DWI lesions (fig. 1). In addition, subacute (DWI hyper- and apparent diffusion coefficient iso- or hyperintense) and chronic ischemic lesions were assessed. Images were reviewed independently by two stroke neurologists (C.J.S. and K.S.). In cases of discrepancy, the final pattern classification was reached by mutual agreement of the readers.
Fig. 1

Characterization of DWI lesion patterns according to number and localization. a Single acute lesion. b Multiple acute lesions in one vascular territory with (micro-) embolic scattering of infarction. c Multiple acute lesions in >1 vascular territory (bihemispheric anterior circulation lesions) without (micro-) embolic scattering of infarction. d Multiple acute lesions in >1 vascular territory (bihemispheric anterior circulation lesions) with (micro-) embolic scattering of infarction. e Multiple acute lesions in >1 vascular territory (anterior and posterior circulation lesions) with (micro-) embolic scattering of infarction.

Stroke Etiology

Before inclusion, the patients were phenotypically characterized according to the ASCOD classification [10]. The prior ASCO phenotypic classification of stroke has shown good concordance with the most widely used Trial of Org 10172 in Acute Stroke Treatment classification [11]. Additionally, the ASCOD classification reflects important supplementary information. Patients with a competing stroke mechanism, defined by the presence of an ASCOD phenotype A (for atherothrombosis), S (for small vessel disease), C (for cardiac pathology), O (for other causes) or D (for dissection) graded 1 or 2 were excluded from the analysis. With respect to the suspected cancer-related stroke mechanisms, exceptions were made for patients with ‘no direct cardiac source identified, but multiple brain infarction, repeated either bilateral or in two different arterial territories (e.g. both anterior and posterior circulation)’, classified C2 according to the ASCOD classification, and nonbacterial thrombotic ‘endocarditis’, classified C1 according to the ASCOD classification.

Ethical Considerations

The study was approved by the local institutional ethics committee (Medizinische Ethikkomission II der Medizinischen Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg).

Results

Patient Characteristics and D-Dimer Assessment

Thirty-two patients (16 male, 16 female) met the inclusion criteria and were included in the analysis. The mean age was 68.7 years. Lung carcinoma was most frequently observed (n = 13, 40%), followed by colorectal carcinoma (n = 4, 12.5%), gastric carcinoma (n = 4, 12.5%) and cancer of an unknown primary (CUP; n = 4, 12.5%). Three patients (9%) suffered from pancreatic carcinoma, 2 (6%) from prostate cancer and 1 patient each from renal (3%) and ovarian (3%) carcinoma. None of the included patients or control subjects showed imaging evidence or clinical syndrome suggestive of cerebral vein thrombosis or primary intracerebral hemorrhage as these patients were not considered in the study per se. Metastatic disease, earlier considered as an additional stroke risk factor [4], was present in 29/32 (90%) patients. The mean D-dimer levels were assessed with a routine coagulation test and were 15.39 µg/ml (±10.84) after a lower cutoff value of 3 µg/ml had been defined for patient inclusion. The time between admittance to hospital and D-dimer assessment was 2.1 days (±2.2) on average.

MRI Categorization

MRI demonstrated acute ischemic lesions in ≥2 vascular territories in 27/32 (84%) patients. Additionally, (micro-) embolic scattering of infarction, as visualized in figure 1, was present in 25/32 (78%) patients. Examples of DWI lesion patterns, characterized according to number and localization, are given in figure 1. The results of acute ischemic lesion patterns are summarized in detail in table 1.
Table 1

MRI categorization

Single infarc tion, nMultiple acute lesions in 1 territory, nMultiple acute lesions in >1 vascular territory, nTotal, n
Total232732
Lesions in anterior and posterior circulation002525
Lesions in bilateral anterior circulation002525
Additional subacute lesions in the same territory001212
Additional subacute lesions in an additional territory1034
Additional chronic lesions in the same territory001111
Additional chronic lesions in an additional territory0235
Cerebral metastasis0033
Additional (micro-) embolic scattering022325
As an indication of recurrent strokes, 16/32 (46%) patients presented with additional subacute infarction. The same number of patients (16/32, 46%) also showed evidence of chronic infarction. The distribution of lesion patterns is additionally visualized in figure 2.
Fig. 2

Distribution of ischemic lesion patterns. Categorized into ‘Single infarction’, ‘Multiple lesions in one vascular territory’ and ‘Multiple lesions in >1 vascular territory’. The frequency of lesions on ‘bilateral anterior circulation’ and ‘anterior and posterior circulation’ is additionally visualized as well as the frequency of ‘additional subacute lesions’ and ‘chronic lesions’.

Three patients (8.5%) showed additional evidence of cerebral metastasis. In all of these cases, ischemic lesions could be easily distinguished from cerebral metastasis. One patient showed extensive cerebral metastasis and was therefore excluded from the analysis.

Discussion

As the diagnosis of cancer-related stroke is strongly dependent on its phenotype, its specification is of highest importance. Especially the lack of recognition of a possibly cancer-related ischemic stroke pattern may prevent the identification of the present cancer-related stroke mechanisms and may be a reason for the undervaluation of this important phenomenon in cancer patients with stroke. Currently, evidence of hypercoagulation and the presence of active malignancy in the absence of conventional stroke mechanisms such as atrial fibrillation or large vessel disease dominate the diagnostic criteria of cancer-related ischemic stroke [10]. Looking at these diagnostic criteria, DWI lesion patterns have received little attention, even though distinct DWI lesion patterns with involvement of multiple vascular territories have been reported repeatedly in cancer-related stroke [4,12,13]. This may be due to the fact that these lesion patterns have never been addressed in detail in a selected cohort of cancer patients with evidence of hypercoagulation before. Our data shows that after the exclusion of competing embolic and nonembolic stroke etiologies, DWI lesions in multiple vascular supply territories strongly dominate the phenotype of cancer-related stroke, being observed in 84% of all patients included in this analysis. Additionally, (micro-) embolic scattering is a frequent feature of ischemic infarction in this special cohort of patients (being observed in 78% of all patients included in this analysis). This is well in line with previous results showing an elevated prevalence of embolic signal detected by transcranial Doppler monitoring in cancer patients in up to 58% and associated with increased D-dimer levels [14]. Our results also confirm the common pathophysiological perception of recurrent cerebral (micro-) embolization due to cancer-related hypercoagulation as leading cause of cancer-related ischemic stroke. Furthermore, our data shows that signs of recurrent embolization on MRI by the detection of infarction at variable stages (acute, subacute or chronic) are also common in cancer patients with evidence of hypercoagulation and without competing stroke etiologies. This is consistent with other data, reporting an increased risk of new DWI lesions in patients with multiple territory lesions at initial presentation [15]. As multiple DWI lesions have been shown to be associated with an increased risk of recurrent stroke [16], this finding may emphasize the urgency of validated strategies for secondary prevention of ischemic stroke in these patients. This conclusion supports preliminary findings concerning the elevated risk of recurrent stroke in cancer patients [17,18]. However, these strategies still need to be established by prospective, randomized and controlled data. In the meantime, in selected individuals, the strategy for secondary prevention may be deduced from data concerning secondary prevention of venous thromboembolism in cancer patients [19,20]. With respect to this data, treatment with low-molecular-weight heparin is currently recommended as first-line therapy by the engaged medical societies [21]. In conclusion, (micro-) embolic scattering of DWI lesions in multiple vascular supply territories and in variable stages appear to be an important aspect of the phenotype of cancer-related stroke and are worth being considered in the diagnostic criteria. These results are not only important for the diagnosis of cancer-related stroke itself but potentially also for identifying cancer-related stroke patients with unknown malignancy at the time of stroke manifestation, which, however, remains to be addressed by a separate prospective approach.

Disclosure Statement

None of the authors have a conflict of interest related to the present study.
  20 in total

1.  Comparison of the new ASCO classification with the TOAST classification in a population with acute ischemic stroke.

Authors:  M E Wolf; T Sauer; A Alonso; M G Hennerici
Journal:  J Neurol       Date:  2011-12-07       Impact factor: 4.849

2.  Clinical manifestation of cancer related stroke: retrospective case-control study.

Authors:  Jeong-Min Kim; Keun-Hwa Jung; Kee Hong Park; Soon-Tae Lee; Kon Chu; Jae-Kyu Roh
Journal:  J Neurooncol       Date:  2013-01-09       Impact factor: 4.130

3.  Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology.

Authors:  Christopher J Schwarzbach; Anke Schaefer; Anne Ebert; Valentin Held; Manuel Bolognese; Micha Kablau; Michael G Hennerici; Marc Fatar
Journal:  Stroke       Date:  2012-09-20       Impact factor: 7.914

4.  Lung cancer and incidence of stroke: a population-based cohort study.

Authors:  Pei-Chun Chen; Chih-Hsin Muo; Yuan-Teh Lee; Yang-Hao Yu; Fung-Chang Sung
Journal:  Stroke       Date:  2011-09-08       Impact factor: 7.914

5.  Acute stroke patterns in patients with internal carotid artery disease: a diffusion-weighted magnetic resonance imaging study.

Authors:  K Szabo; R Kern; A Gass; J Hirsch; M Hennerici
Journal:  Stroke       Date:  2001-06       Impact factor: 7.914

Review 6.  Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

Authors:  Elie A Akl; Srinivasa Rao Vasireddi; Sameer Gunukula; Maddalena Barba; Francesca Sperati; Irene Terrenato; Paola Muti; Holger Schünemann
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

7.  Yield of diffusion-weighted MRI for detection of potentially relevant findings in stroke patients.

Authors:  G W Albers; M G Lansberg; A M Norbash; D C Tong; M W O'Brien; A R Woolfenden; M P Marks; M E Moseley
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

8.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Authors:  Gary H Lyman; Kari Bohlke; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Mark R Somerfield; Anna Falanga
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 9.  Diffusion-weighted MRI for the "small stuff": the details of acute cerebral ischaemia.

Authors:  Achim Gass; Hakan Ay; Kristina Szabo; Walter J Koroshetz
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

10.  Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes.

Authors:  Oh Young Bang; Jin Myoung Seok; Seon Gyeong Kim; Ji Man Hong; Hahn Young Kim; Jun Lee; Pil-Wook Chung; Kwang-Yeol Park; Gyeong-Moon Kim; Chin-Sang Chung; Kwang Ho Lee
Journal:  J Clin Neurol       Date:  2011-06-28       Impact factor: 3.077

View more
  9 in total

Review 1.  Cancer and stroke: commonly encountered by clinicians, but little evidence to guide clinical approach.

Authors:  Malin Woock; Nicolas Martinez-Majander; David J Seiffge; Henriette Aurora Selvik; Annika Nordanstig; Petra Redfors; Erik Lindgren; Mayte Sanchez van Kammen; Alexandros Rentzos; Jonathan M Coutinho; Karen Doyle; Halvor Naess; Jukka Putaala; Katarina Jood; Turgut Tatlisumak
Journal:  Ther Adv Neurol Disord       Date:  2022-06-28       Impact factor: 6.430

2.  Clinical significance of acute and chronic ischaemic lesions in multiple cerebral vascular territories.

Authors:  Hebun Erdur; Lennart S Milles; Jan F Scheitz; Kersten Villringer; Karl Georg Haeusler; Matthias Endres; Heinrich J Audebert; Jochen B Fiebach; Christian H Nolte
Journal:  Eur Radiol       Date:  2018-08-23       Impact factor: 5.315

3.  Predictors of 30-day mortality and the risk of recurrent systemic thromboembolism in cancer patients suffering acute ischemic stroke.

Authors:  Ki-Woong Nam; Chi Kyung Kim; Tae Jung Kim; Sang Joon An; Kyungmi Oh; Heejung Mo; Min Kyoung Kang; Moon-Ku Han; Andrew M Demchuk; Sang-Bae Ko; Byung-Woo Yoon
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

4.  The biomarkers and potential pathogenesis of lung cancer related cerebral hemorrhage.

Authors:  Kemin Qin; Yicong Chen; Haiyin Long; Jiyun Chen; Dacheng Wang; Li Chen; Zhijian Liang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Effects of intracranial atherosclerosis and atrial fibrillation on the prognosis of ischemic stroke with active cancer.

Authors:  Ki-Woong Nam; Hyung-Min Kwon; Yong-Seok Lee
Journal:  PLoS One       Date:  2021-11-05       Impact factor: 3.240

Review 6.  MR imaging findings in some rare neurological complications of paediatric cancer.

Authors:  Tetsuhiko Okabe; Taiki Nozaki; Noriko Aida; Jay Starkey; Mikako Enokizono; Tetsu Niwa; Atsuhiko Handa; Yuji Numaguchi; Yasuyuki Kurihara
Journal:  Insights Imaging       Date:  2018-05-15

7.  Changes in Serial D-Dimer Levels Predict the Prognoses of Trousseau's Syndrome Patients.

Authors:  Shinji Ito; Koichi Kikuchi; Akihiro Ueda; Ryunosuke Nagao; Toshiki Maeda; Kenichiro Murate; Sayuri Shima; Yasuaki Mizutani; Yoshiki Niimi; Tatsuro Mutoh
Journal:  Front Neurol       Date:  2018-07-03       Impact factor: 4.003

8.  Biomarkers and potential pathogenesis of colorectal cancer-related ischemic stroke.

Authors:  Qi-Xiong Qin; Xue-Min Cheng; Li-Zhi Lu; Yun-Fei Wei; Da-Cheng Wang; Hai-Hua Li; Guo-Hui Li; Hong-Bin Liang; Sheng-Yu Li; Li Chen; Zhi-Jian Liang
Journal:  World J Gastroenterol       Date:  2018-11-21       Impact factor: 5.742

9.  Cancer is associated with inferior outcome in patients with ischemic stroke.

Authors:  Alessia Hug; Sung Ju Weber; Katharina Seystahl; Sandra Kapitza; Dorothee Gramatzki; Miriam Wanner; Mira Katan; Andreas R Luft; Sabine Rohrmann; Susanne Wegener; Michael Weller
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.